tbuckley/cabot-search huggingface dataset:
Abstract 17824: Self-Reported Physical Activity and Coronary Microvascular Dysfunction Are Not Associated in Women With Angina and No Obstructive Coronary Artery Disease
Authors: Anna B Rask, Marie M Michelsen, Adam Pena, Naja D Mygind, Daria Frestad, Hannah Elena Suhrs, Ida Gustafsson, Henrik S Hansen, Jens Kastrup, Peter R Hansen, Eva Prescott
Journal: Circulation (2016)

Introduction: Coronary microvascular dysfunction (CMD) is associated with increased cardiovascular morbidity and mortality. The pathophysiology behind CMD remains unknown. Physical inactivity incre...
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
Authors: Carle Paul, Christopher E.M. Griffiths, Peter C.M. van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich
Journal: Journal of the American Academy of Dermatology (2018)
Abstract 10467: Distinct Distribution of Functional Calcium Channels Revealed by Super-resolution Scanning Patch-clamp in Adult Rat Atrial Cardiomyocytes
Authors: Alexey V Glukhov, Marina Balycheva, Sophie Schobesberger, Zeki Ilkan, Anamika Bhargava, Giuseppe Faggian, Julia Gorelik
Journal: Circulation (2013)

Background:  Specific spatial distribution of L-type calcium channels (LTCCs) in ventricular myocytes is known to be crucial for EC coupling. However little is known about the spatial distribution of functional LTCCs in atria. Also the extent of the t-tubular (TT) network in atrial cardiomyocytes in comparison with the well-developed TT network in ventricle remains debatable.   Methods:  Confocal microscopy and scanning ion conductance microscopy were used to characterize cell surface topography and TTs in isolated rat atrial myocytes. Ventricular myocytes were used as control cells as they have a well-studied TT system. Super-resolution scanning patch-clamp was applied to identify distribution of functional LTCCs in different subcellular domains. Spontaneous Ca2+ transient events were promoted by Ca2+ loading by 1 min of 4-Hz pacing and optically visualized by Ca2+-sensitive fluorescent dye Fluo-4 AM.   Results:  About one half of the studied atrial myocytes had TTs, most of them located in the left atrium. Myocytes with TTs (density: 17.3±0.5%) and well-developed surface topography had a larger mean diameter (19.4±1.3μm) than cells with disorganized TTs (density: 12.7±0.5%, P=0.006) or absent TTs and non-structured areas on the surface (16.2±0.6μm, P=0.021, and 12.2±0.4μm, P   Conclusions:  This study provides the first direct evidence of distinct distribution of functional LTCCs within the specific, subcellular compartments of atrial versus ventricular myocytes and offers new insights into the molecular mechanisms of unique atrial myocyte calcium cycling.
Abstract LB-202: Role of the FOXA transcription factors in shaping distinct transcriptional programs in human pancreatic cancers
Authors: Marta Milan, Gioacchino Natoli
Journal: Cancer Research (2018)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer and is characterized by a high intra-tumor heterogeneity, with the coexistence of well- and poorly-differentiated cells in virtually all the tumor cases. FOXA1/2 play a fundamental role in pancreas development and are believed to act as pioneer factors, namely to create accessible chromatin by displacing nucleosomes early in development and making genomic regulatory elements available to other transcriptional regulators. Therefore, we asked whether FOXA1/2 also control differentiation in human PDAC. Whereas FOXA1 showed a remarkable propensity to be expressed selectively by well-differentiated tumor areas and cell lines, FOXA2 showed a broad profile of expression throughout PDAC stages. Through the combination of genomic and functional assays we found that FOXA2 contributed to activate distinct transcriptional programs in tumor cells of different grades. Such complexity in FOXA2 activity specifically depended on its interaction with distinct transcription factors selectively expressed in high- or low-grade tumor cells. While in low-grade (well-differentiated) PDAC cells FOXA2 binding specificity relied on the interaction with the epithelial transcription factor HNF1beta, in high-grade cells it depended on the cooperation with HOXB8 and HOXB9. Knocking out these transcription factors was sufficient to abolish differential recruitment of FOXA2 to grade specific genomic sites. In summary, we found that FOXA2 is broadly express throughout PDAC stages and, through the interaction with different transcription factors, shapes the transcriptional program of the different tumor grades in pancreatic cancer. These findings help to shed light on the complexity of PDAC heterogeneity and on the circuitries that maintain PDAC differentiation and grading. Citation Format: Marta Milan, Gioacchino Natoli. Role of the FOXA transcription factors in shaping distinct transcriptional programs in human pancreatic cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-202.
Abstract 1457: SCAP/SREBP-1 regulates lipid metabolism reprogramming in cancer cell
Authors: chunming cheng, feng geng, xiang cheng, arnab chakravarti, deliang guo
Journal: Cancer Research (2018)

Abstract Warburg initial observation shows tumorigenesis is associated with an increased glucose consumption. Recently, accumulating evidence show that lipid metabolism is reprogrammed in cancers. Elevated lipogenesis which contributes to the development of malignant phenotypes is known to meet requirements for cancer cell rapid growth. However, how they interact to promote cancer growth remain unclear. Through biochemistry and molecular biology assays, we find that EGFR signaling, by increasing glucose uptake, promotes N-glycosylation of sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) and consequent activation of SREBP-1, an ER-bound transcription factor with central roles in lipid metabolism. N-glycosylation promotes SCAP stabilization and dissociates from Insig-1, allowing movement of SCAP/SREBP to the Golgi and consequent SREBP activation. Blocking SCAP N-glycosylation ameliorates EGFRvIII-driven glioblastoma growth in xenograft mouse model. These results show glucose consumption and lipogenesis are linked as reciprocal metabolic cross-talk in tumorigenesis, and targeting SCAP and its N-glycosylation may provide a promising means of more effective cancer therapy. Citation Format: chunming cheng, feng geng, xiang cheng, arnab chakravarti, deliang guo. SCAP/SREBP-1 regulates lipid metabolism reprogramming in cancer cell [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1457.
Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS
Authors: Murielle Grégoire, Fabrice Uhel, Mathieu Lesouhaitier, Arnaud Gacouin, Marion Guirriec, Frederic Mourcin, Erwan Dumontet, Arnaud Chalin, Michel Samson, Laure-Line Berthelot, Adrien Tissot, Mallorie Kerjouan, Stéphane Jouneau, Yves Le Tulzo, Karin Tarte, Jaroslaw W. Zmijewski, Jean-Marc Tadié
Journal: European Respiratory Journal (2018)

Exaggerated release of neutrophil extracellular traps (NETs) along with decreased NET clearance and inability to remove apoptotic cells (efferocytosis) may contribute to sustained inflammation in acute respiratory distress syndrome (ARDS). Recent studies in experimental models of ARDS have revealed the crosstalk between AMP-activated protein kinase (AMPK) and high-mobility group box 1 (HMGB1), which may contribute to effectiveness of efferocytosis, thereby reducing inflammation and ARDS severity.We investigated neutrophil and NET clearance by macrophages from control and ARDS patients and examined how bronchoalveolar lavage (BAL) fluid from control and ARDS patients could affect NET formation and efferocytosis. Metformin (an AMPK activator) and neutralising antibody against HMGB1 were applied to improve efferocytosis and NET clearance.Neutrophils from ARDS patients showed significantly reduced apoptosis. Conversely, NET formation was significantly enhanced in ARDS patients. Exposure of neutrophils to ARDS BAL fluid promoted NET production, while control BAL fluid had no effect. Macrophage engulfment of NETs and apoptotic neutrophils was diminished in ARDS patients. Notably, activation of AMPK in macrophages or neutralisation of HMGB1 in BAL fluid improved efferocytosis and NET clearance.In conclusion, restoration of AMPK activity with metformin or specific neutralisation of HMGB1 in BAL fluid represent promising therapeutic strategies to decrease sustained lung inflammation during ARDS.
Abstract 4524: Immunohistochemistry and alternative FISH testing in breast cancer with <i>HER2</i> equivocal amplification
Authors: Sally Agersborg, Christopher Mixon, Thanh Nguyen, Sramila Aithal, Forrest Blocker, Lawrence Weiss, Robert Gasparini, Shiping Jiang, Wayne Chen, Gregory Hess, Maher Albitar
Journal: Cancer Research (2018)

Abstract PURPOSE While HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by IHC and FISH. Alternative probes may be used in equivocal cases. We present a single community-based institution's experience in further evaluating these cases. PATIENTS AND METHODS Between 2014-2016, 4255 samples were submitted for HER2 amplification testing by alternative probes, TP53, RAI1, and RARA. Of patients tested by FISH, 505/3908 (12.9%) also had IHC data. RESULTS Most (73.9%) FISH equivocal cases remained equivocal after IHC testing. Duplicate testing by IHC using a different paraffin block resulted in poor reproducibility as 44% of IHC negative became equivocal and 40% of IHC equivocal became negative. Of the equivocal cases by IHC, 52.3% became positive by alternative FISH. However, 50.5% of cases equivocal by conventional FISH were classified as HER2 amplified by alternative probes. Most cases were positive by more than one probe; 78% of positive cases were positive by RAI1 and 73.9% by TP53. There was a significant difference between IHC and FISH alternative testing (P&amp;lt;0.0001) among the equivocal cases by conventional FISH testing, 44% of IHC negative cases became positive while 36% of the positive IHC cases became negative by alternative FISH testing. Available data showed that 41% of patients were treated with palbociclib and were positive by alternative FISH. CONCLUSION The prevalence of double HER2 equivocal cases and the discrepancy between IHC and alternative FISH testing suggest that FISH alternative testing using both RAI1 and TP53 probes is necessary for conclusive classification. Due to the significant difference between IHC repeat testing, reflexing on IHC alone in this group of cases may not be reproducible. Because almost half of FISH equivocal cases converted to HER2 amplified upon alternative testing, clinical studies to determine benefit of anti-HER2 therapy in these patients is urgently needed. Alternative FISHIHC Score 0 NegativeIHC Score 1 NegativeIHC Score 2 EquivocalIHC Score 3 PositiveNo%No%No%No%Negative1463.65454.517847.7436.4Positive836.44545.519552.3763.6Total22100.099100.0373100.011100.0 Citation Format: Sally Agersborg, Christopher Mixon, Thanh Nguyen, Sramila Aithal, Forrest Blocker, Lawrence Weiss, Robert Gasparini, Shiping Jiang, Wayne Chen, Gregory Hess, Maher Albitar. Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4524.
Population structure of invasive Neisseria meningitidis in the United States, 2011–15
Authors: Caelin C. Potts, Sandeep J. Joseph, How-Yi Chang, Alexander Chen, Jeni Vuong, Fang Hu, Laurel T. Jenkins, Susanna Schmink, Amy Blain, Jessica R. MacNeil, Lee H. Harrison, Xin Wang
Journal: Journal of Infection (2018)
Database Selection and Heterogeneity—More Details, More Credibility
Authors: Tian Li, Shuai Jiang, Yang Yang
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 259: Integrated multi-omics analyses reveal α-lipoic acid-regulated cell proliferation via Grb2-mediated signaling in colorectal cancer cells
Authors: Lan Yang, Chunlei Hu, Guoqing LV, Bei Li, Shaowei Xiong
Journal: Cancer Research (2018)

Abstract Background: The use of antioxidants as cancer prevention and treatment agents has become a focus of research in recent years due to their limited adverse effects. Alpha lipoic acid (α-LA), a naturally occurring antioxidant and metabolic enzyme co-factor, has been reported to inhibit the growth of various cancer cells, but the precise signaling pathways that mediate the effects of α-LA on colorectal cancer cells development remain unclear. Methods: In this study, we combined the use of an RNA sequencing (RNA-Seq) database and isobaric tag for relative and absolute quantitation (iTRAQ)-based quantitative proteomics data to investigate the dynamic genomic/proteomic response of human colorectal cancer cells (HT29) to α-LA stress. The CCK-8 assay was used to assess cell proliferation in CRC cell lines after α-LA treatment. The expression of proteins were evaluated by western blotting. Grb2 levels were restored in α-LA-treated cells by transfection of a plasmid carrying Grb2 and were reduced in CRC cells via specific siRNA-mediated knockdown. Results: A total of 4,107 differentially expressed genes (2,259 downregulated and 1,848 upregulated) were identified via RNA-Seq in HT29 after exposure to α-LA for 24 h. Moreover, GO and KEGG pathway analyses showed that cancer-relevant cell membrane proteins were significantly affected. An interaction network analysis predicted that Grb2 may mediate the key target pathways activated by exposure to α-LA. In verifying the multi-omics results, Grb2 was confirmed to mediate the α-LA-induced inhibition of cell proliferation in vitro. Moreover, additional experiments indicated that Grb2 inhibition partially abolished EGF-induced phospho-EGFR and phospho-ERK1/2 activity. Furthermore, the analysis of human colorectal cancer specimens obtained from the GEO database showed that the expression of EGFR correlated with that of Grb2. Conclusion: These findings provide a novel mechanism by which α-LA regulates cell colorectal cancer proliferation via the down-regulation of growth factor-stimulated Grb2 signaling. Citation Format: Lan Yang, Chunlei Hu, Guoqing LV, Bei Li, Shaowei Xiong. Integrated multi-omics analyses reveal α-lipoic acid-regulated cell proliferation via Grb2-mediated signaling in colorectal cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 259.
Strengthening the Case for the Role of Thrombophilia in Calciphylaxis
Authors: LaTonya J. Hickson, Robert D. McBane, Rokea A. el-Azhary
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Ultrasound-Guided Cannulation of the Subclavian Vein
Authors: Peter M. Schulman, Neal S. Gerstein, Matthias J. Merkel, Dana A. Braner, Ken Tegtmeyer
Journal: New England Journal of Medicine (2018)

Real-time, ultrasound-guided cannulation of the subclavian vein has advantages over the landmark-guided technique. This video demonstrates the equipment and techniques used in the performance of real-time, ultrasound-guided cannulation of the subclavian vein.
Value of information analyses for real-time prioritization decisions within a cancer clinical trials cooperative group.
Authors: Caroline Savage Bennette, Scott David Ramsey, David Leroy Veenstra, Anirban Basu, Josh John Carlson
Journal: Journal of Clinical Oncology (2015)

6506 Background: Cancer clinical trials groups face excess demand for limited research funds and patient populations. Value of Information (VOI) analyses are an emerging methodology that can help align research investments with areas that could have the greatest impact on patient outcomes, but many questions remain concerning its feasibility and acceptability to inform real-world research prioritization decisions. Our objective was to develop and assess a process for calculating VOI in
Abstract CT151: TTFields and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study
Authors: Minesh Mehta, Vinai Gondi, Manmeet Ahluwalia, Paul D. Brown
Journal: Cancer Research (2018)

Abstract Tumor Treating Fields (TTFields) are non-invasive, loco-regional, anti-mitotic treatment modality, based on low intensity alternating electric fields. Efficacy of TTFields in non-small cell lung cancer (NSCLC) has been demonstrated in multiple in vitro and in vivo models, and in a phase I/II clinical study. TTFields treatment to the brain was safe and extended overall survival in newly-diagnosed glioblastoma patients. The study [NCT02831959] objectives are to test the efficacy, safety and neurocognitive outcomes of TTFields in this patient population. Patients (N=270) with 1-10 brain metastases (BM) from NSCLC are randomized 1:1 to stereotactic radio surgery (SRS) followed by TTFields or supportive care. Patients are followed-up every two months until 2nd intracranial progression. Patients in the control arm may cross over to TTFields at the time of 2nd intracranial progression. Key inclusion criteria: KPS ≥70, 1 inoperable or 2-10 brain lesions amenable to SRS, optimal standard therapy for the extracranial disease, no brain-directed therapy, no signs of significantly increased intracranial pressure, and no electronic implantable devices in the brain. Endpoints included time to 1st intracranial progression or neurological death (primary); time to neurocognitive failure, HVLT, COWAT and TMT); overall survival; radiological response rate; quality-of-life; and adverse events. Treatment comprised continuous TTFields at 150 kHz for &amp;gt; 18 hours/day applied to the brain within 7 days of SRS. The treatment system is a portable medical device allowing normal daily activities. The device delivers TTFields to the brain using 4 Transducer Arrays, which may be covered by a wig or hat. Patients receive the best standard of care for their systemic disease. Statistical Considerations: This is a prospective, randomized, multicenter study. The sample size (N=270) was calculated using a log-rank test (Lakatos 1988 and 2002) with 80% power at a two sided alpha of 0.05 to detect a hazard ratio of 0.57. Citation Format: Minesh Mehta, Vinai Gondi, Manmeet Ahluwalia,, Paul D. Brown. TTFields and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT151.
Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer
Authors: Srinivas R. Viswanathan, Marina F. Nogueira, Colin G. Buss, John M. Krill-Burger, Mathias J. Wawer, Edyta Malolepsza, Ashton C. Berger, Peter S. Choi, Juliann Shih, Alison M. Taylor, Benjamin Tanenbaum, Chandra Sekhar Pedamallu, Andrew D. Cherniack, Pablo Tamayo, Craig A. Strathdee, Kasper Lage, Steven A. Carr, Monica Schenone, Sangeeta N. Bhatia, Francisca Vazquez, Aviad Tsherniak, William C. Hahn, Matthew Meyerson
Journal: Nature Genetics (2018)